Clinical Trials Logo

Stage IIIC Melanoma clinical trials

View clinical trials related to Stage IIIC Melanoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06190249 Not yet recruiting - Stage IIIC Melanoma Clinical Trials

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen, followed by Pembrolizumab.